EUVIMEDEUVIMED entdecken
Crossref

Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration

Noah Benjamin Nagar, Michael Ostrovsky, Nir Shoham-Hazon, Raman Tuli, Thomas Kin Man Lee, Noy Buchnick, Sagiv Beluga, Luiza Bramnik, Eilon Shcolnik, Shalhevet Goldfeather Ben Zaken, Niv Levy, Mor Bareket und 1 weitere

Graefe's Archive for Clinical and Experimental Ophthalmology · 02.07.2026

DOI: 10.1007/s00417-026-07360-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 02.07.2026. Verfasst von Noah Benjamin Nagar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel. noahbenjaminagar@gmail.com. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare real-world effectiveness of faricimab versus aflibercept as second-line therapies for neovascular age-related macular degeneration (nAMD). METHODS: This multicenter retrospective cohort study included patients with nAMD who switched to faricimab or aflibercept as second-line anti-VEGF therapy and were followed ≥ 12 months. Outcomes included best-corrected visual acuity (BCVA, logMAR), central macular thickness (CMT, µm), injection intervals, and switching rates. Multivariable linear regression identified predictors of visual and anatomical change. RESULTS: A total of 170 eyes (84 faricimab, 86 aflibercept) were analyzed. Faricimab-treated eyes had worse baseline BCVA (0.60 ± 0.49 vs. 0.47 ± 0.37 logMAR; p = 0.048) and numerically lower baseline CMT (332.7 ± 107.9 vs. 367.5 ± 103.5 μm; p = 0.057). At final follow-up, faricimab achieved a significant BCVA gain (- 0.16 ± 0.42 logMAR; p < 0.001), while aflibercept maintained stable vision (p = 0.923). Both agents significantly reduced CMT (p < 0.001), with a greater mean reduction observed in the aflibercept group (- 96.7 ± 127.5 vs. - 56.8 ± 132.0 μm; p = 0.046). Final BCVA and CMT did not differ significantly between groups. Final injection intervals were similar between groups (7.5 ± 2.9 vs. 7.6 ± 3.1 weeks; p = 0.906), and switching to third-line therapy occurred less frequently in the faricimab group (4.8% vs. 12.8%; p = 0.065). Baseline BCVA predicted visual gain (B = - 0.199; p = 0.010) and baseline CMT predicted anatomical improvement (B = - 0.517; p < 0.001). CONCLUSION: In this real-world multicenter cohort, both faricimab and aflibercept were associated with visual and anatomical improvement after switching to second-line therapy for nAMD. No statistically significant difference in final BCVA, final CMT or injection interval was observed between treatment groups. Baseline disease severity predicted treatment response. Given the retrospective design and residual confounding, these findings should be interpreted as associative rather than causal.

Schlagwörter

Stichwörter der Autor:innen

AfliberceptAnti-VEGF therapyFaricimabNeovascular age-related macular degenerationReal-world evidence

Autor:innen und Institutionen

  • Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel. noahbenjaminagar@gmail.com.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. noahbenjaminagar@gmail.com.
  • Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Dalhousie University Nova Scotia, Eye NB Centre of Excellence, Miramichi, New Brunswick, Canada.
  • Department of Ophthalmology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Zitieren

APA

Nagar, N. B., Ostrovsky, M., Shoham-Hazon, N., Tuli, R., Lee, T. K. M., Buchnick, N., Beluga, S., Bramnik, L., Shcolnik, E., Goldfeather Ben Zaken, S., Levy, N., Bareket, M., & Berco, E. (2026). Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-026-07360-8

Vancouver

Nagar NB, Ostrovsky M, Shoham-Hazon N, Tuli R, Lee TKM, Buchnick N, et al. Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026. doi:10.1007/s00417-026-07360-8

BibTeX
@article{Nagar2026,
  author = {Nagar, Noah Benjamin and Ostrovsky, Michael and Shoham-Hazon, Nir and Tuli, Raman and Lee, Thomas Kin Man and Buchnick, Noy and Beluga, Sagiv and Bramnik, Luiza and Shcolnik, Eilon and Goldfeather Ben Zaken, Shalhevet and Levy, Niv and Bareket, Mor and Berco, Efraim},
  title = {Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2026},
  doi = {10.1007/s00417-026-07360-8}
}
Kostenlos starten →